Grape King Bio Ltd (TPE:1707)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
122.00
-1.00 (-0.81%)
Mar 3, 2026, 10:35 AM CST
-18.67%
Market Cap 18.22B
Revenue (ttm) 10.40B
Net Income (ttm) 1.22B
Shares Out 148.14M
EPS (ttm) 8.19
PE Ratio 15.01
Forward PE 13.39
Dividend 6.40 (5.16%)
Ex-Dividend Date Jan 8, 2026
Volume 3,000
Average Volume 108,947
Open 123.00
Previous Close 123.00
Day's Range 122.00 - 123.50
52-Week Range 119.50 - 150.50
Beta 0.38
RSI 55.81
Earnings Date Feb 23, 2026

About Grape King Bio

Grape King Bio Ltd, together with its subsidiaries, produces and sells pharmaceutical preparations, patent medicines, liquid tonics, drinks, and healthy food in Taiwan, China, and internationally. It operates through Multi-Level Marketing; Distributors; Original Design Manufacturer/Original Equipment Manufacturer; and Sales Channel segments. The company offers Chinese herbal medicines, probiotics, energy drinks, and health food supplements for gastrointestinal health, immunity regulation, female beauty, and health care. It also provides functio... [Read more]

Sector Healthcare
Founded 1969
Employees 501
Stock Exchange Taiwan Stock Exchange
Ticker Symbol 1707
Full Company Profile

Financial Performance

In 2024, Grape King Bio's revenue was 11.16 billion, an increase of 4.93% compared to the previous year's 10.64 billion. Earnings were 1.45 billion, a decrease of -0.30%.

Financial Statements

News

There is no news available yet.